MIMS publishes summary of new NICE diabetes guidance

A quick-reference MIMS summary of the recently revised NICE guidance on the management of type II diabetes in adults has been added to MIMS.

The new MIMS summary of the guidance is available online and will appear in the March print issue of MIMS.
The new MIMS summary of the guidance is available online and will appear in the March print issue of MIMS.

The updated guidance, which replaces that issued in 2009, places increased importance on individualising care for patients with type II diabetes and includes new recommendations on the sequence of drug treatments that can be offered.

The new MIMS summary of the guidance is available online and will appear in the March print issue of MIMS.

Managing HbA1c levels

Further information
View antidiabetic drug records
View insulin drug records
NICE diabetes guidance
MIMS Diabetes Clinic

The guidance advises that patients should be involved in decisions regarding their individual HbA1c targets and that this decision should take into account personal preferences, comorbidities, risks from polypharmacy and the ability to benefit from long-term interventions due to reduced life expectancy. Patients should then be offered lifestyle advice and drug treatment to support them to achieve and maintain their target HbA1c.

HbA1c levels should be monitored at three- to six-monthly intervals until levels are stable on unchanging therapy, and at six-monthly intervals thereafter. If HbA1c levels are not controlled with a single drug and rise to 58mmol/mol (7.5%) or more, healthcare professionals should reinforce advice about diet, lifestyle and drug adherence and intensify drug treatment with the aim of reducing HbA1c to 53mmol/mol (7%).

Drug treatment

The revised guidance states that all patients with type II diabetes should be offered standard-release metformin as initial treatment, with a gradual increase in dose over several weeks to minimise the risk of gastrointestinal side-effects. If gastrointestinal intolerance occurs, prescribers should consider a trial of modified-release metformin as an alternative.

If metformin is contraindicated or not tolerated, patients may begin drug treatment with a dipeptidyl peptidase-4 (DPP4) inhibitor, pioglitazone or a sulfonylurea.

Treatment intensification

Both treatment pathways, whether beginning with standard-release metformin or with an alternative treatment, have two intensification steps. The metformin pathway features dual therapy (metformin plus one of four options) as the first intensification, followed by triple therapy (all metformin-based options) or insulin-based treatment as the second intensification. In the non-metformin pathway the first intensification comprises dual therapy (three suggested options) with insulin-based treatment as the second intensification.

Insulin-based treatment

The revised guidance includes advice on starting insulin-based treatments using a structured programme involving active insulin dose titration encompassing a number of points, from injection technique to management of hypoglycaemia. The guidance also includes recommendations on switching between the various types of insulin preparations available dependent on response, adverse effects and individual patient preference.

Brush up on the latest clinical guidelines at our MIMS Learning Essentials events

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more